11 drugs piled up over the evaluation of more than 100 million varieties in the list of positive day sunny core hepatitis B medicine.

Author . . . As of July 31, there were 2,249 CDE acceptance and consistency evaluation acceptance numbers (533 varieties of 588 enterprises, the same as below according to supplementary applications), 639 acceptance numbers have been adopted; From May to July 31, the consistency evaluation of drugs by enterprises seemed to have entered an intensive harvest period, with 11 varieties from 10 enterprises stacked up for the first time, and 16 acceptance numbers (12 varieties) were undertaken.
review details of 11 varieties have been evaluated, Zheng Daqing added the first over-rated varieties last week, there are 11 varieties through consistency evaluation, of which 4 varieties for the first over-evaluation, 4 varieties of the second over-evaluation, 1 variety set of three, and 2 varieties of the fourth and fifth, respectively; Drug 4 approved production, as through the consistency evaluation, more details are as follows: this week's consistency evaluation of the details of the table cephalosporine slow release tablets cephalosporine slow release tablets are the second generation of cephalosporine drugs, national Class B medical insurance drugs, applicable to sensitive pathogens caused by the following infections: acute bronchitis and chronic bronchitis acute attacks, pharyngitis, tonsillitis, pneumonia, sinusitis, simple urinary tract infection, skin soft tissue infection.
original research enterprises for Lilly.
Pharmaceutical data show that the current cephalospora slow release film domestic market approval has 6, involving 6 production enterprises, in 2019 domestic sample hospital sales of 118 million yuan, of which Zhejiang Anlikang and Shandong Zibo Xinda Pharmaceuticals accounted for the largest proportion, respectively, 28.98 percent, 26.57 percent;
it is worth mentioning that at present only Zhejiang Anlikang Pharmaceutical declaration consistency evaluation and the first over-evaluation, improve product competitiveness at the same time, or will further eat into market share.
Tymishatan tablets for mithathan specific angiotensin II. Receptor (AT1 type) antagonists, the only FDA and EMEA approved ARB drugs with comprehensive cardiovascular protection adaptation, is the longest plasma half-life angiotensin receptor blocker;
public data show that in 2017 only in China's public medical institutions terminal for Mishatan tablet sales of more than 1 billion yuan, according to the pharmaceutical data enterprise version of hospital sales data show that in 2019 for the domestic sample hospital sales of 415 million yuan, of which the original research enterprises accounted for 77.5 percent, import substitution is extremely inadequate, and it is understood that the original research price is 3 to 5 times the price of domestic generic drugs.
At present, there are 53 approvals for the Mishatan film market, involving 40 manufacturers, of which only 5 enterprises declared consistency evaluation was accepted, Shanghai Xinyi balance pharmaceutical industry's first review, is expected to break the barriers of the original research.
Timisatan tablet consistency evaluation report acceptance details hydrochloric acid zocitridine capsule zocitridine is the only antihistamine drug in China, the original development agent by UCA first listed in Germany in 2001, and then listed in the United Kingdom, the United States, France and other countries.
At present, there are a variety of oral dosage forms of zocitridin hydrochloric acid, such as: tablets, granules, capsules, etc., of which the hydrochloric acid zoscitridine tablets have been evaluated by 6 enterprises, Hunan Jiusai Pharmaceuticals, and it is worth mentioning that the hydrochloric acid zoscitridin tablets for the whole country One of the second round of drug collection, Hunan Jiuyuan with 1.38 yuan / 5mg x 24 pieces of ultra-low bid price (equivalent to 0.057 yuan / piece) to remove Beijing, Heilongjiang, Shanghai, Jiangsu, Anhui, Guangdong, Yunnan and other provinces of the supply market.
The current exclusive dosage form of zocitridine hydrochloric acid in Hunan Province is the first to form a complementary form with tablets through consistent evaluation, further consolidating its share of antihistamine drugs market.
addition, last week's Hunan Nine-Year-Old has a second sodium sodium soluble tablets through a consistent evaluation, can be said to be a good thing.
adforve ester capsule adefovir esters are clinically commonly used nucleoside anti-hepatitis B drugs.
the original research enterprise for GlaxoSmithKly, listed in China in 2005, the current domestic Adelfowe esters tablets and capsules two dosage forms, including the original research enterprises, including 7 domestic manufacturers approved Adelfowe ester capsule market approval.
according to the drug-intelligence consistency evaluation progress database shows that at present, only Zheng Datianqing and Beijing Shuangyan Pharmaceuticals declared the consistency evaluation of the variety, zheng Daqing first passed.
data show that the domestic treatment of hepatitis B drugs are divided into interferon and nucleoside drugs.
Of these, nucleoside drugs account for about 80% of the market share, drug intelligence data show that in 2019 domestic sample hospital Adelfowe ester capsule sample hospital sales reached 325 million yuan, of which more than 90% of the market share was occupied by Zhengda Qing, is now the first day of the variety through consistency evaluation, further consolidate the market position of the variety.
Hydrochloric acidoxetine intestinal soluble capsule hydrochloric acidoxetine is a selective 5-serotonin (5-HT) and no-adrenaline (NE) reuptake inhibitor for the nervous system, suitable for the treatment of depression, generalized anxiety disorders and chronic musculoskeletal pain.
research enterprises for Lilly, in August 2006 has been approved to import China, the commodity named Xin Baida, 2019 sales of 725 million U.S. dollars.
According to pharmaceutical intelligence data, the current domestic enterprises with the approval number of the breed Chengdu Beit, on the drug Chinese and Western pharmaceutical, and are in accordance with the new four types of chemical drugs approved production, is now the stone medicine Oyi followed closely, approved production at the same time as through consistency evaluation, successfully joined the queue of deer-based original research.
it is understood that stone pharmaceutical group generic drug consistency evaluation work into the intensive harvest period, this year, has announced 9 varieties of 14 products have been evaluated.
, 3 varieties of the first evaluation, 4 varieties of the second over-evaluation.
declaration acceptance of 12 varieties were undertaken, injection with cephalosporine sodium declaration enterprises up to 19 last week CDE new consistency evaluation acceptance number 16 (12 varieties), of which 3 varieties are the first to declare accepted varieties, respectively, Large Pharmaceutical's osteopool softgels, Shanghai Sino-Western Pharmaceutical's hydroxychloroquine tablets, Tianjin Zhongxin Pharmaceutical Group Co., Ltd.'s new pharmaceutical plant sulfate bili tablets;
this week's consistency evaluation filing details, the injection consistency evaluation of the most competitive injection of cephalosporine sodium and injection sodium vitola sodium added another competitor.
According to drug intelligence data, up to now 19 enterprises with 52 injection cephalosporine sodium acceptance number consistency evaluation acceptance number by CDE, is currently the injection consistency evaluation declaration acceptance number of the largest varieties;
.